Dexmedetomidine as an Additive for (Ipack)Block in Knee Surgery
NCT ID: NCT07058493
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2024-01-02
2024-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perineural Dexmedetomidine in Adductor Canal Block
NCT03030950
Single-shot Adductor Canal Block With Levobupivacaine and Dexmedetomidine in Total Knee Arthroplasty
NCT04968392
Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.
NCT02089932
Comparison Between Adjuvants Added to Bupivacaine in Adductor Canal Block
NCT04892420
Compare Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided ACB for Postoperative Analgesia After Knee Surgeries
NCT07240402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
. (IPACK) block is a motor power sparing procedure that involves injecting local anesthetic into the space between the popliteal artery and the posterior capsule of the knee in order to treat posterior knee pain
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine
IPACK block with 20ml bupivacaine 0.25% alone.
.
Bupivacaine
20 ml of bupivacaine 0.25%.
Dexmedetomidine
IPACK block with 20 ml of bupivacaine 0.25% with dexmedetomidine 100 μg as adjuvant.
Dexmedetomidine
dexmedetomidine 100 μg as adjuvant to IPACK block with 20 ml of bupivacaine 0.25%.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
dexmedetomidine 100 μg as adjuvant to IPACK block with 20 ml of bupivacaine 0.25%.
Bupivacaine
20 ml of bupivacaine 0.25%.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA I, II .patients undergoing knee surgeries.
Exclusion Criteria
* bleeding disorders
* skin lesion
* infection
* known allergy
* contradictions of spinal anesthesia
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dalia Ismail
Associate Professor of Anesthesia, Surgical ICU and pain management at Faculty of medicine Cairo University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dalia K Ismail
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of medicine Cairo university
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-491-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.